Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core

Prostate

Volumn 66, Issue 7, 2006, Pages 718-727

  Kawai, Noriyasu ^a   Ito, Akira ^b   Nakahara, Yoko ^b   Honda, Hiroyuki ^b   Kobayashi, Takeshi ^b   Futakuchi, Mitsuru ^b   Shirai, Tomoyuki ^a   Tozawa, Keiichi ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Complete regression; Ferrite core; Human prostate cancer; Hyperthermia; Magnetite cationic liposome

Indexed keywords

CATION; FERRITE; LIPOSOME; MAGNETITE; MAGNETITE CATIONIC LIPOSOME; UNCLASSIFIED DRUG;

ADOLESCENT; ALTERNATING CURRENT; ALTERNATING MAGNETIC FIELD; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL STRAIN; CELL STRAIN LNCAP; CELL STRAIN PC 3; CONTROLLED STUDY; DEVICE; ELECTROMAGNETIC FIELD; EXPERIMENTAL NEOPLASM; FERRITE CORE INSERTED SOLENOID; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; REPEATED HYPERTHERMIA;

ANIMALS; COMBINED MODALITY THERAPY; FERROSOFERRIC OXIDE; HYPERTHERMIA, INDUCED; INDICATORS AND REAGENTS; IRON; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; TEMPERATURE; TREATMENT OUTCOME;

EID: 33645898296     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20394     Document Type: Article

References (35)

1. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Changed trends of cancer mortality in the elderly. Ann Oncol 2001;12: 1467-1477.
2. Littrup PJ. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society. Cancer 1997;80:1864-1870.
3. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997;80:1835-1844.
4. Schellhammer PF. Editorial: Improving outcomes for primary and salvage therapy of localized prostate cancer. J Urol 2003; 170:1841-1842.
5. Akaza H, Homma Y, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Ohashi Y, Aso Y. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: A prospective and randomized study. The Prostate Cancer Study Group. Jpn J Clin Oncol 2000;30:131-136.
6. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zinck eH, Belldegrun AS. Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 2003;170:1126-1130.
7. Chin JL, Tourna N, Pautler SE, Guram KS, Bella AJ, Downey DB, Moussa M. Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J Urol 2003;170:1199-1202.
8. Johnson DB, Nakada SY. Cryoablation of renal and prostate tumors. J Endourol 2003;17:627-632.
9. Rouviere O, Lyonnet D, Radiant A, Colin-Pan gaud C, Chapelon JY, Bouvier R. Dubernard JM, Gelet A. MRl appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001;40:265-274.
10. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results. J Urol 1999;161: 156-162.
11. Van Leenders GJ, Beerlage HP, Ruijter ET, de la Rosette JJ, van de Kaa CA. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J Clin Pathol 2000;53:391-394.
12. Van der Zee J. Heating the patient: A promising approach? Ann Oncol 2002;13:1173-1184.
13. Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T. Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 1986;58:1589-1595.
14. Kroeze H, van de Kamer JB, de Leeuw AA, Kikuchi M, Lagendijk JJ. Treatment planning for capacitive regional hyperthermia. Int J Hyperthermia 2003;19:58-73.
15. Sherar MD, Gertner MR, Yue CK, O'Malley ME, Toi A, Gladman AS, Davidson SR, Trachtenberg J. Interstitial microwave thermal therapy for prostate cancer: Method of treatment and results of a phase I/II trial. J Urol 2001;166:1707-1714.
16. Tucker RD, Huidobro C, Larson T, Platz CE. Use of permanent interstitial temperature self-regulating rods for ablation of prostate cancer. J Endourol 2000;14:511-517.
17. Master VA, Shinohara K, Carroll PR. Ferromagnetic thermal ablation of locally recurrent prostate cancer: Prostate specific antigen results and immediate/intermediate morbidities. J Urol 2004;172:2197-2202.
18. Deger S, Taymoorian K, Boehmer D, Schink T, Roigas J, Wille AH, Budach V, Wernecke KD, Loening SA. Thermoradiotherapy using interstitial self-regulating thermoseeds: An intermediate analysis of a phase II trial. Eur Urol 2004;45:574-579.
19. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: Current status and future directions. Int J Hyperthermia 2002;18:267-284.
20. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: In vitro study. Jpn J Cancer Res 1996;87:1179-1183.
21. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: Ex vivo study. Jpn J Cancer Res 1997;88:630-632.
22. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: An in vivo study. Jpn J Cancer Res 1998;89:463-469.
23. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res 1998;89:775-782.
24. Kawai N, Ito A, Nakahara Y, Futakuchi M, Shirai T, Honda H, Kobayashi T, Kohri K. Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 2005;64:373-381.
25. Shinkai M, Ueda K, Ohtsu S, Honda H, Kobayashi T. Effect of functional magnetid particles on frequency capative heating. Japanese Journal of Cancer Research 1999; 90:699-704.
26. Cetas TC, Gross EJ, Contractor Y. A ferrite core/metallic sheath thermoseed for interstitial thermal therapies. IEEE Transactions on Biomedical Engineering 1998;45:68-77.
27. Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosciences and Bioengneering 2003; 4:364-369.
28. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
29. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
30. Nakanoma T, Ueno M, Iida M, Hirata R, Deguchi N. Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells. Human cell 2001;11:623-630.
31. Kasamon KM, Dawson NA. Update on hormone-refractory prostate cancer. Curr Opin Urol 2004;14:185-193.
32. Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 2004;5:303-313.
33. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969;23:24-34.
34. Byar DP, Mostofi FK. Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 1972; 30:5-13.
35. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non palpable (stage Tie) prostate cancer. JAMA 1994;271:368-374.